OPEN-ACCESS PEER-REVIEWED

1Dr Harshkumar Patel, 2Dr Jyothi Vybhavi V S, 3Dr Samreen Farooqui, 4Dr Renju Ravi, 5Dr Jitendra Patel

Junior Resident, Department of Medicine, GMERS Medical College and Hospital, Vadnagar, Gujarat, India

Associate Professor, Department of Physiology, Sri Chamundeswari Medical College Hospital & Research Institute, Channapatna, Ramanagara District, Karnataka, India

Assistant Professor, Department of Physiology, College of Medicine, Jazan University, Jazan, KSA

Department of Clinical Pharmacology, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia

Associate Professor, Department of Physiology, GMERS Medical College and Hospital, Vadnagar, Gujarat, India

Download PDF

Abstract

Numerous drugs can affect thyroid function. When a patient needs exogenous levothyroxine, the majority of these drugs either directly affect the thyroid or have an impact on the absorption and metabolism of thyroid hormones. Thyroid-stimulating hormone (TSH) in the hypothalamus or thyrotrope can be reduced by a certain class of drugs, which includes glucocorticoids, dopamine agonists, somatostatin analogs, and rexinoids. This can then affect thyroid function. Thankfully, most of these medications usually do not cause central hypothyroidism that is clinically noticeable. Most patients with rexinoids, a more modern class of nuclear hormone receptor agonists, experience clinically severe central hypothyroidism. Dopamine agonists may worsen “hypothyroidism” in people with nonthyroidal disorders. The main aim is to review the Central Hypothyroidism causing drugs. This systematic review aims to inventory and analyze the literature on medications associated with central hypothyroidism. The review will focus on understanding the potential causal relationship between various drugs and the emergence of central hypothyroidism. The strategy outlined below will guide the thorough search, selection, and analysis of relevant research. The discussion underscores the complexity of medication-induced central hypothyroidism and stresses the necessity of cautious assessment and treatment in a therapeutic context, taking into account the various and frequently transient effects of these drugs on thyroid function.

Keywords: Central Hypothyroidism, Drugs, Thyroid

References

[1]. Know more. Feel better. [Internet]. Verywell Health. 2020. Available from: https://www.verywellhealth.com/

[2]. SINGH BK, YEN PM. A clinician’s guide to understanding resistance to thyroid hormone due to receptor mutations in the TRα and TRβ isoforms. Clinical Diabetes and Endocrinology [Internet]. 2017 Sep 15;3(1). Available from: https://doi.org/10.1186/s40842-017-0046-z

[3]. VISSER TJ. Regulation of thyroid function, synthesis, and function of thyroid hormones. In: Endocrinology [Internet]. 2018. p. 3–32. Available from: https://doi.org/10.1007/978-3-319-45013-1_1

[4]. CHIAMOLERA MI, WONDISFORD FE. Thyrotropin-Releasing hormone and the thyroid hormone feedback mechanism. Endocrinology [Internet]. 2009 Jan 29;150(3):1091–6. Available from: https://doi.org/10.1210/en.2008-1795

[5]. MONTANELLI L, BENVENGA S, HEGEDŰS L, VITTI P, LATROFA F, DUNTAS L. Drugs and Other Substances Interfering with Thyroid Function. In: Endocrinology [Internet]. 2018. p. 1–29. Available from: https://doi.org/10.1007/978-3-319-29195-6_27-1

[6]. CLEGG DJ, BROWN LM, WOODS SC, BENOIT SC. Gonadal hormones determine sensitivity to central leptin and insulin. Diabetes [Internet]. 2006 Apr 1;55(4):978–87. Available from: https://doi.org/10.2337/diabetes.55.04.06.db05-1339

[7]. YAMADA M, MORI M. Mechanisms related to the pathophysiology and management of central hypothyroidism. Nature Clinical Practice Endocrinology & Metabolism [Internet]. 2008 Oct 21;4(12):683–94. Available from: https://doi.org/10. 1038/ncpendmet0995

[8]. LANIA A, PERSANI L, BECK‐PECCOZ P. Central hypothyroidism. Pituitary [Internet]. 2008 Apr 16;11(2):181–6. Available from: https://doi.org/10.1007/s11102-008-0122-6

[9]. ROSE SR. Cranial irradiation and central hypothyroidism. Trends in Endocrinology and Metabolism [Internet]. 2001 Apr 1;12(3):97–104. Available from: https://doi.org/10.1016/s1043-2760(00)00359-3

[10]. BRAVERMAN LE, COOPER D. Werner & Ingbar The Thyroid. Lippincott Williams & Wilkins; 2012.

[11]. PERSANI L. Central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. The Journal of Clinical Endocrinology & Metabolism [Internet]. 2012 Sep 1;97(9):3068–78. Available from: https://doi.org/10.1210/ jc.2012-1616

[12]. ZWAVELING-SOONAWALA N, VAN TROTSENBURG ASP, VERKERK PH. TSH and FT4 concentrations in congenital central hypothyroidism and mild congenital thyroidal hypothyroidism. The Journal of Clinical Endocrinology & Metabolism [Internet]. 2018 Jan 9; Available from: https://doi.org/10.1210/jc.2017-01577

[13]. PRICE A. Screening for central hypothyroidism is unjustified. The BMJ [Internet]. 2001 Mar 31;322(7289):798. Available from: https://doi.org/10.1136/bmj.322.7289.798

[14]. Central Hypothyroidism – Endocrinology Advisor [Internet]. [cited 2024Feb.27]. Available from: https://www.endocrinology advisor.com/ddi/central-hypothyroidism/

[15]. SURKS MI, SIEVERT R. Drugs and thyroid function. The New England Journal of Medicine [Internet]. 1995 Dec 21;333(25):1688–94. Available from: https://doi.org/10.1056/ nejm199512213332507

[16]. CUI Q, BIAN R, XU F, LIU Q, WANG W, BIAN Q. New molecular entities and structure–activity relationships of drugs designed by the natural product derivatization method from 2010 to 2018. In: Studies in natural products chemistry [Internet]. 2021. p. 371–415. Available from: https://doi.org/10.1016/b978-0-12-819487-4.00016-1

[17]. Glucocorticoid Receptor – Endotext – NCBI Bookshelf [Internet]. [cited 2024Feb.27]. Available from: https://www.ncbi.nlm.nih. gov/books/NBK279171/

[18]. MEIJER OC, BUURSTEDE JC, SCHAAF MJM. Corticosteroid receptors in the brain: Transcriptional Mechanisms for Specificity and Context-Dependent Effects. Cellular and Molecular Neurobiology [Internet]. 2018 Oct 5;39(4):539–49. Available from: https://doi.org/10.1007/s10571-018-0625-2

[19]. Glucocorticoids: List, Uses, Side Effects, and More [Internet]. [cited 2024Feb.27]. Available from: https://www.healthline. com/ health/glucocorticoids

[20]. LEIGH RM. Cortisol. Rumi Michael Leigh; 2022.

[21]. TIMMERMANS S, SOUFFRIAU J, LIBERT C. A General Introduction to Glucocorticoid Biology. Frontiers in Immunology [Internet]. 2019 Jul 4;10. Available from: https://doi.org/10. 3389/fimmu.2019.01545

[22]. BROOKS DJ. Dopamine agonists: their role in the treatment of Parkinson’s disease. Journal of Neurology, Neurosurgery, and Psychiatry [Internet]. 2000 Jun 1;68(6):685–9. Available from: https://doi.org/10.1136/jnnp.68.6.685

[23]. CHOI J, HORNER KA. Dopamine agonists [Internet]. StatPearls – NCBI Bookshelf. 2023. Available from: https://www.ncbi. nlm.nih.gov/books/NBK551686/

[24]. MBBS SM. Somatostatin analogs: drug class, uses, side effects, drug names [Internet]. RxList. 2022. Available from: https://www.rxlist.com /somatostatin_analogs/drug-class.htm

[25]. FREDA PU. Somatostatin analogs in acromegaly. The Journal of Clinical Endocrinology & Metabolism [Internet]. 2002 Jul 1;87(7):3013–8. Available from: https://doi.org/10.1210/ jcem.87.7.8665

[26]. GOMES-PORRAS M, CÁRDENAS‐SALAS J, ÁLVAREZ-ESCOLÁ C. Somatostatin Analogs in Clinical Practice: A review. International Journal of Molecular Sciences [Internet]. 2020 Feb 29;21(5):1682. Available from: https://doi.org/10.3390/ ijms21051682

[27]. LEAL AS, REICH LA, MOERLAND JA, ZHANG D, LIBY KT. Potential therapeutic uses of rexinoids. In: Advances in pharmacology [Internet]. 2021. p. 141–83. Available from: https://doi.org/10. 1016/bs.apha.2021.01.004

[28]. Atigadda VR, Xia G, Deshpande AM, Wu L, Kedishvili NY, Smith CD, et al. Conformationally defined rexinoids and their efficacy in the prevention of mammary cancers. Journal of Medicinal Chemistry [Internet]. 2015 Sep 22;58(19):7763–74. Available from: https://doi.org/10.1021/ acs.jmedchem.5b00829

[29]. REICH LA, MOERLAND JA, LEAL AS, ZHANG D, CARAPELLUCCI S, LOCKWOOD B, et al. The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer. Scientific Reports [Internet]. 2022 Jan 7;12(1). Available from: https://doi.org/10.1038/s41598-021-04415-0

[30]. MOERLAND JA, ZHANG D, REICH LA, CARAPELLUCCI S, LOCKWOOD B, LEAL AS, et al. The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer. Scientific Reports [Internet]. 2020 Dec 17;10(1). Available from: https://doi.org/10.1038/s41598-020-79260-8

[31]. SMITH M. Glucocorticoids. In: Elsevier eBooks [Internet]. 2009. p. 249–59. Available from: https://doi.org/10.1016/b978-032304679-4.10013-9

[32]. SHAHID MA, ASHRAF MA, SHARMA S. Physiology, thyroid hormone [Internet]. StatPearls – NCBI Bookshelf. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/ NBK500006/

[33]. NADOLNIK L. Role of glucocorticoids in regulation of iodine metabolism in thyroid gland: Effects of Hyper-And Hypocorticism. In: InTech eBooks [Internet]. 2012. Available from: https://doi.org/10.5772/52043

[34]. WISE JK, HENDLER R, FELIG P. Influence of glucocorticoids on glucagon secretion and plasma amino acid concentrations in Man. Journal of Clinical Investigation [Internet]. 1973 Nov 1;52(11):2774–82. Available from: https://doi.org/10. 1172/jci107473

[35]. JOSEPH‐BRAVO P, JAIMES-HOY L, URIBE RMA, CHARLI J. 60 YEARS OF NEUROENDOCRINOLOGY: TRH, the first hypophysiotropic releasing hormone isolated: control of the pituitary–thyroid axis. Journal of Endocrinology [Internet]. 2015 Jun 22;226(2):T85–100. Available from: https://doi.org/10. 1530/joe-15-0124

[36]. LI J, ZHANG Q. Intrathyroidal feedforward and feedback network regulating thyroid hormone synthesis and secretion. Frontiers in Endocrinology [Internet]. 2022 Sep 15;13. Available from: https://doi.org/10.3389/fendo.2022.992883

[37]. Celebrating 30 years of UpToDate [Internet]. Available from: https://www.uptodate.com/

[38]. Shared.MManuals. The Trusted Provider of Medical Information since 1899 [Internet]. Shared.MManuals. Available from: https://www.msdmanuals.com/

[39]. SHERMAN SI. Etiology, Diagnosis, and Treatment Recommendations for Central Hypothyroidism Associated with Bexarotene Therapy for Cutaneous T-Cell Lymphoma. Clinical Lymphoma [Internet]. 2003 Mar 1;3(4):249–52. Available from: https://doi.org/10.3816/clm.2003.n.006

[40]. MORLEY JE. Neuroendocrine control of thyrotropin secretion. Endocrine Reviews [Internet]. 1981 Oct 1;2(4):396–436. Available from: https://doi.org/10.1210/edrv-2-4-396

[41]. SAMUELS MH, HENRY P, RIDGWAY EC. Effects of dopamine and somatostatin on pulsatile pituitary glycoprotein secretion. The Journal of Clinical Endocrinology & Metabolism [Internet]. 1992 Jan 1;74(1):217–22. Available from: https://doi.org/10.1210/ jcem.74.1.1345783

[42]. OHZEKI T, HANAKI K, MOTOZUMI H, OHTAHARA H, ISHITANI N, URASHIMA H, et al. Efficacy of bromocriptine administration for selective pituitary resistance to thyroid hormone. Hormone Research [Internet]. 1993 Jan 1;39(5–6):229–34. Available from: https://doi.org/10.1159/000182741

[43]. KOK P, ROELFSEMA F, FRÖLICH M, VAN PELT J, MEINDERS AE, PIJL H. Bromocriptine reduces augmented thyrotropin secretion in obese premenopausal women. The Journal of Clinical Endocrinology & Metabolism [Internet]. 2009 Apr 1;94(4):1176–81. Available from: https://doi.org/10.1210 /jc.2008-2303

[44]. LEWIS BM, DIEGÜEZ C, LEWIS M, SCANLON MF. Dopamine stimulates release of thyrotrophin-releasing hormone from perfused intact rat hypothalamus via hypothalamic D2-receptors. Journal of Endocrinology [Internet]. 1987 Dec 1;115(3):419–24. Available from: https://doi.org/10.1677/ joe.0.1150419

[45]. VAN ’T VERLAAT JW, CROUGHS RJM, HENDRIKS MJ, BOSMA NJ, NORTIER JWR, THIJSSEN JHH. Bromocriptine treatment of prolactin secreting macroadenomas: a radiological, ophthalmological and endocrinological study. European Journal of Endocrinology [Internet]. 1986 Aug 1;112(4):487–93. Available from: https://doi.org/10.1530/acta.0.1120487

[46]. GAVRILA A, HOLLENBERG AN. The Hypothalamic-Pituitary-Thyroid Axis: Physiological regulation and clinical implications. In: Springer eBooks [Internet]. 2019. p. 13–23. Available from: https://doi.org/10.1007/978-3-319-72102-6_2

[47]. MOHAMMADI S, DOLATSHAHI M, RAHMANI F. Shedding light on thyroid hormone disorders and Parkinson disease pathology: mechanisms and risk factors. Journal of Endocrinological Investigation [Internet]. 2020 Jun 4;44(1):1–13. Available from: https://doi.org/10.1007/s40618-020-01314-5

[48]. Van Den Berghe G, De Zegher F, Lauwers P. Dopamine and the sick euthyroid syndrome in critical illness. Clinical Endocrinology [Internet]. 1994 Dec 1;41(6):731–7. Available from: https://doi.org/10.1111/j.1365-2265.1994.tb02787.x

[49]. FILIPPI L, PEZZATI M, CECCHI A, SERAFINI L, POGGI C, DANI C, et al. Dopamine infusion and anterior pituitary gland function in very low birth weight infants. Neonatology [Internet]. 2006 Jan 1;89(4):274–80. Available from: https://doi.org/10.1159/000091741

[50]. MANNAVOLA D, PERSANI L, VANNUCCHI G, ZANARDELLI M, FUGAZZOLA L, VERGA U, et al. Different responses to chronic somatostatin analogues in patients with central hyperthyroidism. Clinical Endocrinology [Internet]. 2004 Dec 23;62(2):176–81. Available from: https://doi.org/10.1111/j. 1365-2265.2004.02192.x

[51]. CARON P, ARLOT S, BAUTERS C, CHANSON P, KUHN JM, PUGEAT M, et al. Efficacy of the Long-Acting Octreotide Formulation (Octreotide-Lar) in Patients with Thyrotropin-Secreting Pituitary Adenomas. The Journal of Clinical Endocrinology & Metabolism [Internet]. 2001 Jun 1;86(6):2849–53. Available from: https://doi.org/ 10.1210/ jcem.86.6.7593

[52]. COLAO A, MEROLA B, FERONE D, MARZULLO P, CERBONE G, LONGOBARDI S, et al. Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non-functioning pituitary adenomas. European Journal of Endocrinology [Internet]. 1995 Aug 1;133(2):189–94. Available from: https://doi.org/10.1530/ eje.0.1330189

[53]. ROELFSEMA F, FRÖLICH M. Pulsatile Thyrotropin Release and Thyroid Function in Acromegalics before and during Subcutaneous Octreotide Infusion*. The Journal of Clinical Endocrinology & Metabolism [Internet]. 1991 Jan 1;72(1):77–82. Available from: https://doi.org/10.1210/jcem-72-1-77

[54]. DE MACEDO BM, IZQUIERDO RF, GOLBERT L, MEYER ELS. Reliability of Thyroid Imaging Reporting and Data System (TI-RADS), and ultrasonographic classification of the American Thyroid Association (ATA) in differentiating benign from malignant thyroid nodules. Archives of Endocrinology and Metabolism [Internet]. 2018 Mar 23; Available from: https://doi.org/10.20945/2359-3997000000018

[55]. ROELFSEMA F, FRÖLICH M. Pulsatile Thyrotropin Release and Thyroid Function in Acromegalics before and during Subcutaneous Octreotide Infusion*. The Journal of Clinical Endocrinology & Metabolism [Internet]. 1991 Jan 1;72(1):77–82. Available from: https://doi.org/10 .1210/jcem-72-1-77

[56]. SHERMAN SI, GOPAL J, HAUGEN BR, CHIU AC, WHALEY KJ, NOWLAKHA P, et al. Central Hypothyroidism Associated with Retinoid X Receptor–Selective Ligands. The New England Journal of Medicine [Internet]. 1999 Apr 8;340(14):1075–9. Available from: https://doi.org/10.1056/ nejm19990408340 1404